Journal of Education, Health and Sport (Sep 2024)

Euglycemic diabetes ketoacidosis associated with SGLT-2 inhibitors - review of case reports

  • Joanna Winciorek,
  • Piotr Cyran,
  • Anna Jaroszyńska,
  • Filip Jaroszyński,
  • Joanna Kowal,
  • Jan Paleczny,
  • Robert Parobczak,
  • Paweł Jakub Połujański,
  • Adrianna Marta Wiśniewska

DOI
https://doi.org/10.12775/JEHS.2024.68.55325
Journal volume & issue
Vol. 68

Abstract

Read online

AIM: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have gained significant importance in the treatment of type 2 diabetes mellitus. One of the adverse effects while using SGLT-2 inhibitors is euglycemic ketoacidosis (euDKA) - acute life-threatening emergency. METHODS: The following review of case reports was based on articles published in 2023, obtained from the PubMed databases. Key search terms included “case report”, “sglt-2”, “sglt-2i”, “sodium-glucose cotransporter inhibitors”, “dka”. “eudka”, “euglycemic ketoacidosis”. RESULTS: In the literature, cases of euDKA correlated with the use of SGLT-2 inhibitors are described. CONCLUSION: There is a need for greater observation of the frequency of the adverse effects in patients taking sodium-glucose cotransporter inhibitors (SGLT-2i) and for raising awareness among doctors about the possibility of developing euglycemic diabetic ketoacidosis during the SGLT-2 inhibitors therapy.

Keywords